Kabra Drugs share news and announcements
BSE: 524322Pharmaceuticals & BiotechnologySmall Cap
Last close ₹16.15down ₹0.49 (2.94%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹16.64.
52-week range of traded prices to 23 Oct 2026
₹15.50Low, 23 Oct 2026₹35.52High, 11 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹38 Cr3,225th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 5.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 28.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 28.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day.
- 58,004
Kabra Drugs board meetings
197 filed, newest first. Page 1 of 4.
Sep 2026
2 Sep · Board meeting
Aug 2026
27 Aug · Board meeting
Meeting on 2 Sep 20265 Aug · Board meeting
Meeting on 12 Aug 2026: quarterly results
May 2026
21 May · Board meeting
Meeting on 29 May 2026: quarterly results
Apr 2026
27 Apr · Board meeting
Meeting on 6 May 202610 Apr · Board meeting
Meeting on 21 Apr 2026
Mar 2026
Feb 2026
26 Feb · Board meeting
Meeting on 7 Mar 20266 Feb · Board meeting
Meeting on 13 Feb 2026: quarterly results
Jan 2026
1 Jan · Board meeting
Dec 2025
22 Dec · Board meeting
Meeting on 1 Jan 2026
Nov 2025
20 Nov · Board meeting
Meeting on 28 Nov 20256 Nov · Board meeting
Meeting on 13 Nov 2025: quarterly results
Oct 2025
Sep 2025
24 Sep · Board meeting
Meeting on 8 Oct 2025
Aug 2025
28 Aug · Board meeting
Meeting on 2 Sep 20257 Aug · Board meeting
Meeting on 14 Aug 2025: quarterly results
Jul 2025
31 Jul · Board meeting
Meeting on 6 Aug 2025
Jun 2025
9 Jun · Board meeting
Meeting on 18 Jun 2025
May 2025
23 May · Board meeting
Meeting on 30 May 2025: audited results
Feb 2025
7 Feb · Board meeting
Meeting on 14 Feb 2025: quarterly results
Dec 2024
4 Dec · Board meeting
Nov 2024
25 Nov · Board meeting
Meeting on 4 Dec 20247 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results